Oravax, Inc.

Nov 24, 98
10:32 ET	OraVax, Inc. Files IND For Colitis Vaccine
Nov 17, 98
10:31 ET	Oravax, Inc. Receives Notice Of Delisting From Nasdaq
Nov 16, 98
17:12 ET	OraVax, Inc. Reports 1998 Third Quarter Results
Nov 11, 98
07:59 ET	OraVax, Inc. Announces Plans to Merge With Peptide Therapeutics Group PLC
Sep 21, 98
09:30 ET	OraVax, Inc. Notified of Noncompliance With Listing Requirements of The Nasdaq National Market
Aug 18, 98
16:30 ET	OraVax, Inc. Reports on Status Regarding Initial Program to Manufacture Vaccines for the U.S. Military
Aug 13, 98
16:01 ET	Oravax, Inc. Reports 1998 Second Quarter And Six Months Results
Jul 14, 98
16:00 ET	OraVax Receives U.S. Patent for the Use of a Protein to Detect Highly Virulent Strains of Helicobacter Pylori
May 28, 98
11:15 ET	OraVax Unveils New ChimeriVax Family of Vaccines Against Major Disease Targets
May 26, 98
18:59 ET	OraVax Comments On Heavy Stock Trading
May 11, 98
16:00 ET	Brigid A. Makes Joins OraVax, Inc. as Chief Financial Officer
May 07, 98
17:35 ET	OraVax, Inc. Reports 1998 First Quarter Results
Apr 14, 98
16:00 ET	OraVax Out-Licenses CagA H. pylori Antigen to Biomerica, Inc.
Mar 26, 98
16:01 ET	OraVax, Inc. Reports Fourth-Quarter and Year-End Results
Mar 23, 98
16:00 ET	OraVax, Inc. Stockholders Approve Preferred Stock
Jan 21, 98
17:25 ET	OraVax, Inc. Completes $6.75 Million Private Placement
Oct 29, 97
16:15 ET	OraVax, Inc. to Conduct Phase III Clinical Trial for Respiratory Syncytial Virus in Infants in Winter 1998-1999
Oct 23, 97
08:29 ET	OraVax, Inc. Reports 1997 Third Quarter Results
Oct 20, 97
08:29 ET	NIH Awards OraVax Phase II SBIR Grant for the Clinical Development of New Treatments for Clostridium Difficile Associated Disease
Sep 29, 97
16:05 ET	OraVax And Evans Medical Sign U.S. Marketing And Distribution Agreement For Yellow Fever Vaccine
Sep 16, 97
08:29 ET	OraVax Acquires Chimeric Vaccine Technology From St. Louis University Patent Filing Covers a New Class of Single-Dose Viral Vaccines
Jul 30, 97
16:48 ET	OraVax, Inc. Reports 1997 Second Quarter and Six Months Results
Apr 28, 97
11:28 ET	OraVax President and CEO to Chair Vaccine Conference Sponsored By The Institute For International Research
Apr 25, 97
07:59 ET	OraVax, Inc. Reports 1997 First Quarter Results
Apr 04, 97
14:52 ET	OraVax, Inc. Adopts Shareholder Rights Plan
Apr 03, 97
16:15 ET	OraVax Announces Reorganization; Reduces Operating Costs
Mar 19, 97
06:04 ET	OraVax Reports Results from Phase III Trial of HNK20 Nosedrop for Respiratory Syncytial Virus in Infants
Mar 10, 97
08:50 ET	OraVax Names C. Boyd Clarke, President of U.S. BioScience, to Board of Directors
Mar 03, 97
15:59 ET	OraVax Reports Fourth-Quarter And Year-End Results
Jan 27, 97
10:08 ET	OraVax Researcher to Present at Fourth Annual International Conference on Helicobacter Pylori & Gastroduodenal Disorders
Nov 25, 96
08:02 ET	Complete H. pylori Genome Sequence Licensed to OraVax and Pasteur Merieux Connaught in Exclusive Agreement with MedImmune and Human Genome Sciences
Nov 13, 96
07:29 ET	OraVax Grants bioMerieux Vitek License to CagA Antigen For H. Pylori in Vitro Diagnostic Tests
Oct 23, 96
17:10 ET	OraVax Reports 1996 Third Quarter Results
Oct 17, 96
05:30 ET	OraVax and Pasteur Merieux Connaught Demonstrate Reduction of H. pylori Infection in Subjects Receiving Oral Vaccine
Oct 09, 96
16:11 ET	Oravax's Dr. Lance Gordon Presents Current Trends in Immunization at Partnership for Prevention's October Immunization Conference
Oct 07, 96
09:24 ET	Oravax's Dr. Lance Gordon Presents Current Trends in Immunization at Partnership for Prevention's October Immunization Conference
Sep 26, 96
09:08 ET	OraVax Updates Investors at Cowen & Company's 11th Annual Biotechnology Conference
09:05 ET	OraVax Updates Investors at Cowen & Company's 11th Annual Biotechnology Conference
Aug 07, 96
16:15 ET	OraVax, Inc. Reports 1996 Second Quarter Results
Aug 05, 96
07:59 ET	U.S. Patent Issues For OraVax, Inc.'s Oral Treatment of H. pylori Infection